论文部分内容阅读
目的 :探讨 Apo AI基因启动子多态性与 2型糖尿病 ( DM-2 )伴同冠心病 ( CHD)的关系。方法 :应用聚合酶链反应技术 ,对 3 0例正常对照者、3 0例 CHD患者和 3 1例 DM-2患者及 3 0例 DM-2合并 CHD患者 (合并组 ) ,进行了载脂蛋白 AI基因启动子 -78bp( G/ A) Msp-I酶切位点限制性片段长度多态性 ( RFL P)研究。结果 :等位基因 A在 DM-2组、CHD组、合并组与对照组比较均显著降低 ( 0 .1 61 ,0 .1 83 ,0 .0 83 ,0 .43 0 ) ,A基因频率 DM-2组比合并组稍高 ,但无显著性差异 ( P>0 .0 5 )。结论 :Apo AI基因多态性是 DM-2合并 CHD的遗传标记之一
Objective: To investigate the relationship between Apo AI gene promoter polymorphism and type 2 diabetes mellitus (DM-2) with coronary heart disease (CHD). Methods: Polymerase chain reaction (PCR) was performed in 30 healthy controls, 30 CHD patients and 31 DM-2 patients and 30 DM-2 combined CHD patients (combined group) AI gene promoter-78bp (G / A) Msp-I restriction fragment length restriction fragment length polymorphism (RFLP) study. Results: The allele A was significantly lower in the DM-2 group, the CHD group, the combined group as compared with the control group (0.21 1, 0 1 83, 0 0 83, 0. 43 0), the A gene frequency DM -2 group was slightly higher than the combined group, but no significant difference (P> 0.05). Conclusion: Apo AI gene polymorphism is one of the genetic markers of DM-2 combined CHD